CA-CYOLO
8.5.2024 14:31:36 CEST | Business Wire | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats.
New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access.
This interoperability is designed to provide OT customers visibility and management of their asset inventory and enhance asset vulnerability detection and remediation capabilities through a seamless secure controlled access platform.
“Cyolo ICS/OT security and safety expertise are changing the way organizations understand secure remote access,” said Matt Cowell, VP of Business Development at Dragos. “With our companies’ complementary capabilities and unique strengths, we can manage security through the different layers of the operational environment and protect a wider array of organizations across critical infrastructure. Ultimately reducing risk as they expand connectivity.”
Bringing the Cyolo PRO platform alongside the Dragos OT-native network visibility and monitoring offerings gives an unparalleled advantage. The Dragos Platform enables organizations to scale protection, the threat intelligence to keep on top of current threats, and the tools to respond quickly to incidents. With Cyolo’s robust role-based access, application, and policy control, in the future the Dragos Platform will be able to manage Cyolo’s Identity-based parameters (users, applications, resources, policy) in accordance with SOC / IR policies and guidelines.
Together Cyolo and Dragos deliver a comprehensive ICS/OT security framework based on the five critical controls of effective ICS/OT security:
- ICS incident response—which integrates operational insights into incident handling, enhancing system integrity and recovery (Dragos)
- Defensible architecture—ensuring robust visibility, segmentation, and enforcement mechanisms to bridge technological and human aspects of security (Dragos and Cyolo PRO)
- ICS network visibility monitoring—employing continuous monitoring and protocol-aware tools to detect and address potential vulnerabilities (Dragos)
- Remote Access Security—ensuring safe and secure stringent access control in the face of evolving hybrid work environments (Cyolo PRO)
- Risk-based vulnerability management—prioritizing and addressing vulnerabilities based on their potential to pose significant operational risks, thereby ensuring proactive prevention, response, and recovery actions (Dragos and Cyolo PRO)
The solution plans to integrate Cyolo PRO and the Dragos Platform through an API architecture or operator console. It will deliver unsurpassed visibility and control of critical digital assets through secure identity-based access. Together, both companies will deliver simpler, stronger, and more efficient security controls that lay the foundation for Zero Trust (NIST 800-207).
“With this industry leading partnership, Cyolo joins Dragos to address security and operational challenges impacting OT environments," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. “The interoperability of the Dragos Platform and Cyolo PRO provides OT practitioners and industrial organizations with the full spectrum of cybersecurity services across the 5 ICS/OT Critical Controls. The timing could not be better as the world aggressively embraces Industry 4.0.”
Dino Busalachi, CTO and Co-Founder at Velta Technology - a joint partner - also highlighted that “In light of the surge in cyber threats, the growing adoption of Industry 4.0, and the inherent risks within OT environments, Velta Technology understands the critical need to partner with Cyolo and Dragos. Their joint solutions will provide our customers in the industrial sector with a tailored approach that strengthens their access security and elevates their overall security posture.”
Dragos and Cyolo respond to the need for secure industrial networks without disrupting operations, compromising safety or risking non-compliance.
The Dragos Platform offers the most effective industrial cybersecurity technology, giving customers visibility into their ICS/OT assets, vulnerabilities, threats, and response actions. The strength behind the Dragos Platform comes from Dragos’s ability to codify industry-leading OT threat intelligence, and insights from the Dragos services team into the software.
About Cyolo
Cyolo helps IT and ICS organizations stay secure and productive in an era of distributed workforces and unprecedented cyber threats. Cyolo’s platform enables all users, including employees, third parties, and remote or on-site workers, to connect to their working environments seamlessly and securely via modern identity-based authentication. With one unified solution that integrates with your existing tech stack, Cyolo makes securely connecting people to their work simple. To learn more, visit https://cyolo.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508290964/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
